Actualités

OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy. A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy [...]

Overview of 10 years of practice with CACIPLIQ20® matrix therapy as a healing agent for hard to heal wounds: Efficacy, cost-effectiveness and future perspectives Background: Chronic, non-healing wounds remain a major challenge for health care practitioners and for society in general, both in terms of the enormous economic burden [...]

Merel Gansevoort 1 , SabineWentholt 1, Gaia Li Vecchi 1, Marjolein de Vries 1, Elly M. M. Versteeg 1, Bouke K. H. L. Boekema 2,3 , Agnes Choppin 4, Denis Barritault 4, Franck Chiappini 4 , Toin H. van Kuppevelt 1 and Willeke F. Daamen 1,* Fibrosis after full-thickness wound [...]

Laurie Perdigon (1) , Manon Barthe (1) , Hanan Osman-Ponchet (1) , Agnes Choppin (2) , Franck Chiappini (2) Human precision-cut lung slices (hPCLS) are a promising ex vivo model for respiratory research. These thin, precisely-cut tissues, obtained from fresh lungs using a vibrating microtome, retain the native 3D architecture [...]

Manon Barthe (1) , Laurie Perdigon (1) , Hanan Osman-Ponchet (1) , Agnès Choppin (2) , Franck Chiapini (2) Pulmonary fibrosis is a progressive, restrictive lung disease characterized by scarring and stiffening of lung tissue, ultimately leading to respiratory failure. This condition is driven by the excessive proliferation and migration [...]

Laurie Perdigon (1) , Manon Barthe (1) , Jean-Paul Thénot (1) , Franck Chiappini (2) , Agnes Choppin (2) , Hanan Osman-Ponchet (1) Occurrence of diffuse alveolar damage is a real storm in the course of pulmonary diseases leading to an acute and/or chronic inflammatory processes with poorly understood etiologies [...]